Inhibitory effect of ribbon-type NF-κB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Kunugiza, Yasuo ^a   Tomita, Tetsuya ^a   Tomita, Naruya ^b   Morishita, Ryuichi ^a   Yoshikawa, Hideki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF-KAPPAB DECOY; OLIGODEOXYRIBONUCLEOTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL; ANKLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; DRUG STABILITY; FEMALE; INTRAARTICULAR DRUG ADMINISTRATION; LEWIS RAT; METABOLISM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; RAT;

ANIMALS; ANKLE JOINT; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DOWN-REGULATION; DRUG STABILITY; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; INJECTIONS, INTRA-ARTICULAR; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OLIGODEOXYRIBONUCLEOTIDES; OSTEOCLASTS; RANK LIGAND; RATS; RATS, INBRED LEW;

EID: 70350599225     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1980     Document Type: Article

References (58)

1. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, et al.: A novel molecular mechanism modulating osteoclast differentiation and function Bone 1999, 25:109-113.
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
4. Yao GQ, Sun BH, Hammond EE, Spencer EN, Horowitz MC, Insogna KL, Weir EC: The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. J Biol Chem 1998, 273:4119-4128.
5. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530.
6. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparellic, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
7. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
9. Wei S, Teitelbeum SL, Wang MW-H, Ross FP: Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology 2001, 142:1290-1295.
10. Boyce BF, Xing L, Franzoso G, Siebenlist U: Required and nonessential functions of nuclear factor-kappa B in bone cells. Bone 1999, 25:137-139.
11. Jimi E, Aoki K, Saito H, Acquisto FD, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, et al.: Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004, 10:617-624.
12. Bharti AC, Takada Y, Aggarwal BB: Curcumin (diferuloylmethane) inhibits receptor activator of NF-κB ligand-induced NF-κB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004, 172:5940-5947.
13. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U: Requirement for NF- κB in osteoclast and B-cell development. Genes Dev 1997, 11 3482-3496.
14. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R: Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997, 3 1285-1289.
15. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, Karin M: IκB kinase (IKK)β but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005, 201:1677-1687.
16. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, Koshihara Y: A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997, 240:279-286.
17. Takano H, Tomita T, Totosaki-Maeda T, Maeda-Taniyama M, Tsuboi H, Takeuchi E, Kaneko M, Shi K, Takahi K, Myoui H, et al.: Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. Rheumatology 2004, 43:435-441.
18. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951.
19. Lubberts E, Oppers-Walgreen B, Pettit AR, Bersselaar L, Joosten L, Goldring SR, Gravallese EM, Berg WB: Increase in expression of receptor activator of nuclear factor κB, at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002, 46:3055-3064.
20. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
21. Mann MJ, Dzau VJ: Therapeutic application of transcriptional factor decoy oligonucleotides. J Clin Invest 2000, 106:1071-1075.
22. Dzau VJ: Transcription factor decoy. Circ Res 2002, 90 1234-1236.
23. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, et al.: In vivo transfection of cis element 'decoy'against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 1997, 3:894-899.
24. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, et al.: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor-κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999, 42:2532-2542.
25. Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, Takahi T, Nakase Y, Kaneda Y, Yoshikawa H, Ochi T: Transcription factor decoy for NFκB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000, 39:749-757.
26. Tomita N, Morishita R, Tomita S, Yamamoto K, Aoki M, Matsushita H, Hayashi S, Higaki J, Ogihara T: Transcription factor decoy for nuclear factor-κB inhibits tumor necrosis factor-a-induced expression of interleukin-6 and intracellular adhesion molecule- 1 in endothelial cells. J Hypertens 1998, 16:993-1000.
27. Lee IK, Ahn JD, Kim HS, Park JY, Lee KU: Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr Drug Targets 2003, 4:619-623.
28. Tomita N, Tomita T, Yuyama K, Tougan T, Tajima T, Ogihara T, Morishita R: Development of novel decoy oligonuclAotides: advantages of circular dumb-bell decoy. Curr Opin Mol Ther 2003, 5 107-112.
29. Hosoya T, Takeuchi H, Kanesaka Y, Yamakawa H, Miyano-Kurosaki N, Takai K, Yamamoto N, Takaku H: Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999, 461:136-140.
30. Moon IJ, Choi K, Choi YK, Kim JE, Lee Y, Schreiber AD, Park JG: Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. J Biol Chem 2000, 275 4647-4653.
31. Trentham D, Townes A, Kang A: Autoimmunity to type 2 collagen: an experimental model of arthritis. J Exp Med 1977, 146 857-868.
32. Shiozawa S, Shimizu K, Tanaka K, Hino K: Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997, 99:1210-1216.
33. Rumney SIV, Kool ET: DNA recognition by hybrid oligother-oligodeoxynucleotide macrocycles. Angew Chem Int Ed Engl 1992, 31:1617-1619.
34. Gamper HB, Reed MW, Cox T, Virosco JS, Adams AD, Gall AA, Scholler JK, Meyer RB Jr: Facile preparation of nuclease resistant 3' modified oligodeoxynucleotides. Nucleic Acids Res 1993, 21:145-150.
35. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, et al.: Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3 889-901.
36. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S: Rel/ NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev 1995, 9:2723-2735.
37. Karin M, Delhase M: The IκBKkinase (IKK) and NF-κB: key elements of proinflammatory signaling. Immunology 2000, 12:85-98.
38. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T: Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 1998, 273:8799-8805.
39. Morishita R, Tomita N, Kaneda Y, Ogihara T: Molecular therapy to inhibit NFκB activation by transcription factor decoy oligonucleotides Curr Opin Pharmacol 2004, 4:139-146.
40. Ahn JD, Morishita R, Kaneda Y, Lee SJ, Kwon KY, Choi SY, Lee KU, Park JY, Moon IJ, Park JG, et al.: Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 2002, 90:1325-1332.
41. Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang Y-C, Lee K-U, Kim YH, Lee IK: Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 2002, 9:1682-1692.
42. Park KK, Ahn JD, Lee IK, Magae J, Heintz NH, Kwak JY, Lee YC, Cho YS, Kim HC, Chae YM, et al.: Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Biochem Biophys Res Commun 2003, 308:689-697.
43. Brown DA, Kang SH, Gryaznov SM, Dedionisio L, Heidenreich O, Sullivan S, Xu X, Nerenberg MI: Effect of phosphorothionate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994, 269:26801-26805.
44. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA: Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothionate oligodeoxynucleotides. Nucleic Acids Res 1996, 24:737-745.
45. Chu BCF, Orgel LE: The stability of different forms of doublestranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 1992, 20:5857-5858.
46. Chu BCF, Orgel LE: Binding of hairpin and dumbbell DNA to transcription factors. Nucleic Acids Res 1991, 19:6958.
47. Penolazzi L, Lambertini E, Borgatti M, Piva R, Cozzani M, Giovannini I, Naccari R, Siciliani G, Gambari R: Decoy oligodeoxynucleotides targeting NF-κB transcriptional factors: Induction of apoptosis in human primary osteoclasts. Biochem Pharmacology 2003, 66 1189-1198.
48. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, et al.: Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 2000, 148:333-342.
49. Ishikawa T, Kamiyama M, Tani-ishii N, Suzuki H, Ichikawa Y, Hamaguchi Y, Momiyama N, Shimada H: Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001, 32:84-91.
50. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotideIuptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 1989, 86 6454-6458.
51. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989, 86:3474-3478.
52. Wu-Pong S: Alternative interpretations of the oligonucleotide transport literature: Insights from nature. Adv Drug Deliv Rev 2000, 44:59-70.
53. Zhou B, Cron RQ: Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem 2002, 277:10704-10711.
54. Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, et al.: Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005, 20 653-662.
55. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NF-κB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
56. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltscmidt C, et al.: Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591.
57. Handel ML, McMorrow LB, Gravallese EM: Nuclear factor-κB in rheumatoid synovium. Arthritis Rheum 1995, 38:1762-1770.
58. Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collageninduced arthritis, an animal model of autoimmunity. Life Sci 1997, 61:1861-1878.